Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2, and Phase 3, before it is approved and available to patients. Each phase ...
The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...
Cyprus may still be an unlikely place to build a biotechnology company, but Dr Marianna Prokopi-Demetriades, co-founder and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results